ARS Wealth Advisors’s CorMedix CRMD Stock Holding History

ARS Wealth Advisors’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-10,000	Closed	-$66K	–	132
2020 Q4	$66K	Buy	+10,000	New	+$68K	0.01%	121

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EIM

Elliott Investment Management West Palm Beach, Florida $22.7B AUM 59.88% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

CAM

Cresset Asset Management Chicago, Illinois $27.6B AUM 31.92% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

ARS Wealth Advisors's CRMD Position: Q1 2021 in Review

ARS Wealth Advisors sold out of CorMedix (CRMD) in Q1 2021, closing a stake of 10,000 shares — an estimated $66K sold.

ARS Wealth Advisors first reported a position in CRMD in Q4 2020 and held it in 1 quarter. The position peaked at $66K in Q4 2020. 79 funds tracked by Wall St. Rank hold CRMD as of Q1 2021.

ARS Wealth Advisors reported no remaining CorMedix position as of Q1 2021 after selling out during the quarter.
ARS Wealth Advisors sold 10,000 CorMedix shares in Q1 2021, an estimated $66K.
ARS Wealth Advisors first reported a position in CorMedix in Q4 2020 and held it in 1 quarter.
ARS Wealth Advisors's CorMedix position peaked at $66K in Q4 2020.
79 funds tracked by Wall St. Rank held CorMedix as of Q1 2021.

Based on ARS Wealth Advisors's 13F filing for Q1 2021, filed 18 May 2021.